CPRX Key Stats
- CATALYST PHARMACEUTICAL PARTNERS, INC. Financials May 21
- Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pill May 20
- Catyalyst Pharmaceutical (CPRX) Posts Narrower than Expected Q1 Loss Street Insider May 16
- Catalyst Pharmaceutical Partners Reports First Quarter 2013 Financial Results GlobeNewswire May 16
- CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financi... May 16
- Dr. Reddy's Earnings Increase Y/Y May 15
- FDA Accepts Merck BLA May 15
- CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 10-Q, Quarterly Report May 15
- FDA Accepts Merck BLA - Analyst Blog Zacks May 15
- Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog Zacks May 15
CPRX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Catalyst Pharmaceutical Partners is up 54.37% over the last year vs S&P 500 Total Return up 27.77%, Lannett Company up 218.5%, and Santarus up 281.1%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CPRX
Pro Report PDF for CPRX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CPRX Pro Report PDF
Pro Strategies Featuring CPRX
Did Catalyst Pharmaceutical Partners make it into our Pro Portfolio Strategies?